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Abstract 
Background: Brucellosis is a common disease between humans and 
animals which can cause various types of organ involvement. Of the 
most common and important disorders, it is a skeletal disorder that 
causes severe pain. The aim of this study was done to compare the 
behavioral changes in pain patterns in brucellosis patients under oral 
gabapentin and naproxen treatment. 
Methods: This study was a paralleled randomized controlled clinical 
trial on 86 patients with brucellosis disease. All 15-65-year-old 
patients with diagnosed brucellosis and no history of other systemic 
diseases were included. Patients with a history of using corticosteroids 
were excluded. After receiving their informed consent, the eligible 
patients were randomly divided into two equal groups of intervention 
(gabapentin) and control group (naproxen) using a block 
randomization method. Then, the pain severity was assessed using 
visual analog scale (VAS) before, as well as 4, 7, and 10 days post-
intervention. In this study, the patients, data collector (pain intensity 
assessment), and analyzer were blinded. The data were analyzed using 
repeated measure ANOVA. Significance level was set at 0.05.  
Results: Among the participants, 56 patients (65.1%) were male and 
the mean age of the patients was 46.85 ± 19.15 years, which was not 
significantly different between the two groups. In the case of painful 
and involved joints, sacroiliac joint with 34 cases (39.5%) was the most 
commonly involved joint in both groups. There was a significant 
difference between the two groups regarding the mean pain intensity 
on the fourth day (Pvalue = 0.021) and seventh day (Pvalue = 0.001), 
while there was no difference at other times. 
Conclusions: The results of this study revealed that gabapentin 
significantly and rapidly decreased skeletal pain in brucellosis 
patients. Therefore, it can be used as an appropriate drug for the 
control of bone and joint pain in brucellosis patients, though at least it 
should be used for a few day period. 
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Introduction 
Brucellosis is one of the most common diseases in Iran. 
This disease is a global economic and health problem. Thirty-
five percent of the patients are children under the age of 15 
years.1 This condition is one of the most commonly transmitted 
diseases that can be transmitted between humans and animals 
through direct contact with blood, placenta, fetal and uterine 
secretions of infected animals (cattle, sheep, goats, pigs, camels 
and buffalos), while consumption of contaminated raw animal 
products (especially milk and its products) can be an indirect 
route of transmission to humans.2 Brucellosis bacteria are 
Gram-negative and aerobic coccobacilli that are separated from 
each other by serological and biochemical techniques.1,2 There 
are six main species of brucella which include: Melitansis, 
Suis, Abortis, Canis, Ovis, and Neotome, among which the first 
four species have pathogenic potentials for humans. 
Human brucellosis caused by brucella melitansis (which is 
the most invasive and pathogenic species among the species of 
brucella) occurs in places where infected sheep and goats are a 
serious public health problem. However, due to the extensive 
establishment of pasteurization, brucellosis in many countries 
has changed to a scattered occupational disease among those 
involved in the transport of livestock, such as the veterinarians, 
the staff of laboratories, employees and workers dealing with 
the production and packaging plants of the meat and 
slaughterhouses.1,2 The ways to control of disease are 
predominantly based on disease prevention, and care is a key 
tool for managing the prevention and control of the disease.3 
Most patients with brucellosis show nonspecific symptoms of a 
nervous system disorder such as headache, lethargy, and 
depression. Generally, acute or chronic illness begins with 
continuous or regular fever with varying periods of chills, 
sweating, especially at night, tiredness, loss of appetite and 
hunger, weight loss, headache, and general pain in the body. 
Brucellosis can cause damage to all systems and organs in 
the body, but most of all, the skeletal system, the urinary tract, 
the liver, the heart, the lungs, and the spleen are affected. Bone 
and joint pain is common in brucellosis which are heavily 
persistent. Muscle and skeletal pain occurs in over 85% of 
patients with brucellosis. These pains are present in almost all 
joints of the body, but are more common in the lumbosacral, 
knee, and shoulder belt.4,5 The intensity of the pain is very 
diverse and varies from mild to severe pain and prolonged pain 
where most patients need analgesics to control their pain.4 
Various drugs are used to control arthritis and osteomyelitis 
pain with the most commonly used NSAIDs being diclofenac, 
ibuprofen, indomethacin, Piroxicam, and Naproxen.5,6 
Naproxen is a good anti-inflammatory medicine for bone pain. 
This drug is a potent inhibitor of cyclooxygenase enzyme, 
which converts arachidonic acid into prostaglandins.7,8 This 
medication reduces the production of prostaglandins by 
inhibiting cyclooxygenase and thus has an analgesic and anti-
inflammatory effect.9 The effect of each of these drugs varies 
from person to person, and sometimes does not provide 
satisfactory results in some people.10 Thus, newer drugs should 
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be found to control bone pain in patients with this condition. 
Gabapentin is one of the new drugs used in this field. This 
medication with its central effect mitigates and controls the 
bone pain in brucellosis patients.6 Gabapentin, given its 
analgesic properties, has been able to largely replace other 
drugs in controlling bone and joint pain. It is a gamma amino 
butyric acid (GABA) analogue initially produced for the 
treatment of epilepsy, but is currently used for various uses, 
including pain relief, especially pain with a neurological origin 
(such as headache and back pain) and inflammation (arthritis 
and osteomyelitis).11 Since the extent of this effect is not yet 
clear and due to the high prevalence of brucellosis in this area, 
the aim of this study was to compare the behavioral changes in 
pain patterns in brucellosis patients under oral gabapentin and 
naproxen treatment, admitted to Imam Hossain hospital of 
Shahroud during 2017. 
Materials and Methods  
This study was conducted on all brucellosis patients who 
had severe or fairly severe joint and bone pain and referred to 
Imam Hossain hospital of Shahroud, in north east of Iran from 
March 2017 to August 2017. 
After explaining the purpose of the study and obtaining the 
informed consent, all patients (86 subjects) were randomized. 
Then, the pain intensity of the patients was recorded based on 
Visual Analog scale (VAS) at the beginning of the study on a 
10 cm ruler, with painlessness on the number 0 and the most 
severe pain on the number 10. 
Inclusion criteria: age 15 to 65 years, a definitive diagnosis 
of brucellosis, no history of other systemic diseases (such as 
diabetes or thyroid disease), vascular diseases, coagulation 
problems (such as hemophilia), and history of gastrointestinal 
bleeding and structural disorders (scoliosis and 
spondylolisthesis, etc.), absence of neurological symptoms 
such as straight leg raise (SLR) and positive cross-SLR, 
decreased tendon reflexes and diminished sensation in 
examination, no use of oral or injectable painkillers in the past 
10 days, as well as willingness to enter the study. 
Exclusion criteria: injection of corticosteroids in the waist 
or other areas of the body in a month before and during the 
study, a positive record of opium use, history of the use of 
hypnotic, anti-epileptic, and relaxant drugs in the last two 
weeks, severe hypersensitivity to either of the two drugs 
(gabapentin and naproxen), and lack of consent to continuing 
the cooperation. The flow-diagram of study is shown in figure 1. 
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This randomized, parallel clinical trial was approved by the 
institutional review board of Shahroud University of medical 
sciences (with ethics code: IR. SHMU.REC.1395.72 from the 
ethics committee of Shahroud university of medical sciences 
and research project code: p93/073 from research deputy of 
Shahroud university of medical sciences) and registered in 
Iranian registry of clinical trial. (IRCT registration number: 
IRCT20171124037609N1).  
A questionnaire including demographic and clinical 
information was filled for each eligible patient (n = 86). They 
were randomly allocated into intervention (use of gabapentin) 
and control group (use of naproxen) using blocked 
randomization with size of 4. To conceal the randomization 
sequence, we used sequentially numbered, opaque envelopes. 
In this study, patients, data collector, (pain intensity 
assessment), and analyzer were blinded. 
In the intervention group, 200 mg of gabapentin tablets 
twice daily (400 mg daily) and the control group, 250 mg of 
naproxen tablets twice daily (500 mg daily) were administered. 
Then, the severity of pain was determined using a Visual 
Analog Scale (VAS) on one day before, as well as days 4, 7, 
and 10 post-administrations. 
The variables studied included sex, age, duration of 
brucellosis at the beginning of the study and post-treatment, 
bone pain reduction using VAS, complications following 
treatment by the two drugs, and severe post-treatment pain. 
The sample size was estimated based on various research 
objectives and according to numerous studies such as Kasimcan 
and Levin,12,13 and via the G-Power software version 3.0.10. 
Data analysis was performed based on intention to treat 
analysis by statistical software SPSS version 16. For describing 
the findings, descriptive statistics such as mean, standard 
deviation, and frequency were used. In order to compare the 
two groups at different times, we used repeated measure 
ANOVA. Significance level was set at 0.05. 
Results 
In this study, 86 brucellosis patients participated, where 56 
patients (65.1%) were male and 30 patients (34.9%) were 
female, and the mean age of patients was 46.4 ± 18.8 years. 
There was no significant difference in sex and age between the 
two groups. The clinical and demographic characteristics of the 
patients in the two groups are reported in table 1. The results of 
repeated ANOVA showed that there was an interaction 
between time and group. Thus, we added a Bonferroni post hoc 
test to compare the mean scores between the two groups in 
terms of time intervals. The results of this study revealed that 
the severity of pain at the beginning of the visit and the end of 
the third day post treatment had no significant difference 
between the two groups. However, on the fifth (Pvalue = 
0.021) and seventh days (Pvalue = 0.001), pain severity was 
significantly lower in the intervention group. The results of the 
pain intensity at different times in the two groups are shown in 
tables 2 and 3. 
Table 1. Comparison of demographic data and clinical variables in intervention and control groups 
Pvalue Control group (N = 43) Intervention group(N = 43) Variables 
0.078 45.9± 18.8 47.4± 19.7 Mean age (years) 
 
0.093 
 
27 (62.8%) 
16 (37.2%) 
 
29 (67.4%) 
14 (32.6%) 
Sex 
 Male 
 Female 
0.143 24.9± 4.1 24.2± 3.9 BMI (kg/m2) 
 
0.121 
 
11 (25.6%) 
32 (74.4%) 
 
10 (23.3%) 
33 (76.7%) 
History of diabetic 
 Yes 
 No 
 
0.107 
 
5 (11.6%) 
38 (88.4%) 
 
7 (16.3%) 
36 (83.7%) 
History of skeletal disorders 
 Yes 
 No 
 
0.451 
 
43 (100.0%) 
0 (0.0%) 
 
43 (100.0%) 
0 (100.0%) 
History of analgesic using 
 Yes 
 No 
 
0.081 
 
29 (67.4%) 
14 (32.6%) 
 
27 (62.8%) 
16 (37.2%) 
History of corticosteroid using 
 Yes 
 No 
 
0.083 
 
30 (68.9%) 
13 (31.1%) 
 
28 (64.4%) 
15 (35.6%) 
History of smoking 
 Yes 
 No 
 
0.108 
 
13 (31.1%) 
30 (68.9%) 
 
14 (33.3%) 
29 (66.7%) 
History of addiction 
 Yes 
 No 
0.128 23.6± 20.9 25.2± 19.7 Mean duration of pain (days) 
 
0.083 
 
18 (41.9%) 
11 (25.6%) 
6 (13.9%) 
4 (9.3%) 
4 (9.3%) 
 
16 (37.2%) 
12 (27.9%) 
7 (16.4%) 
3 (6.9%) 
5 (11.6%) 
Place of pain 
 Sacroiliac 
 Lumbosacral 
 Shoulder belt 
 knee 
 Others 
 
0.067 
 
4 (9.3%) 
15 (34.9%) 
24 (55.8%) 
 
5 (11.6%) 
17 (39.5%) 
21 (48.8%) 
Number of joints involved 
 One 
 Two 
 Three and more 
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Table 2. Comparison of mean of pain intensity in two groups at different times of intervention using repeated measure ANOVA 
 
Intervention group 
Mean ± SD 
Control group 
Mean ± SD 
Group Time Interaction of group and time 
Before treatment 8.2 ± 0.6 8.1 ± 0.3    
Fourth day after treatment 7.4 ± 0.3 7.8 ± 0.3 F = 10.3 F = 15.3 F = 21.2 
Seventh day after treatment 4.9 ± 0.2 6.4 ± 0.2 Pvalue = 0.03 Pvalue = 0.01 Pvalue = 0.0.001 
Tenth day after treatment 3.8 ± 0.4 5.7 ± 0.3    
 
 
 
 
Discussion 
In the present study, the patients in the gabapentin group 
received more effective pain control on the seventh and tenth 
days’ post-treatment, but on the fourth day after treatment, the 
pain control did not differ significantly between the two 
groups. Although the exact mechanism for gabapentin in 
reducing bone pain is still unclear, according to studies, it has a 
repressive effect on the central nervous system and can control 
pain centers in the brain through controlling the pain and 
analgesia Induced.12,13 
In a study by Mamalis et al., gabapentin was able to 
effectively control bone pain among 62 patients with different 
degrees of brucellosis.14 Also, the use of gabapentin has also 
been effective in controlling chronic bone pain due to other 
infectious diseases. This, as with the present study, suggests the 
positive effect of this drug on controlling skeletal pain.15,16 
In the study by Mete et al., various types of analgesics, 
especially non-steroidal drugs, were used to reduce skeletal 
pain, such as pain in the lumbosacral joints and pelvic bundle 
in brucellosis, all of which were the same, while gabapentin 
was able to reduce the pain at a greater speed and with a better 
effect. This finding is consistent with the results of our study.17 
In a study by Mehanic et al. on 62 patients with severe 
infectious brucellosis, oral gabapentin administration showed a 
significant decline in skeletal pain and reduced the need for 
other analgesics, especially opium drugs. Eighty percent of the 
patients responded well to gabapentin. There was also a 
reduction in the duration of stay in the department due to 
severe skeletal pain, while also improving the patient function 
and contributing to a faster process for the discharge of patients 
when using this drug. In the present study, less pain was 
observed in the gabapentin group on the fifth and seventh days’ 
post-treatment, which is consistent with the results of the 
Mehanic study.18 
Gabapentin (and Pregabalin), in addition to controlling arthritis 
and bone pain, can also control pain associated with soft tissue 
damage around the joints, as well as ligaments and muscles. It is 
also useful in controlling pain caused by sports injury.19  
In the study by Andrabi et al., the analgesic effects of 
gabapentin in patients undergoing joint surgery due to the 
underlying condition of brucellosis and its associated damage 
were investigated. They confirmed the role of gabapentin in the 
rapid and effective reduction of postoperative pain.20 
In a study by Mrabet et al., who intended to control pain in 
676 patients with various types of skeletal disorders, including 
brucellosis, gabapentin and several non-steroidal anti-
inflammatory drugs (naproxen, indomethacin and diclofenac 
sodium) were used comparatively. The results showed that 
gabapentin more effectively reduced the pain of these patients 
and it was more effective than the other drugs used, which is 
consistent with the results of the present study.21 
In a study by Yilmaz and Cerit, the administration of 
injected gabapentin was effective in relieving skeletal pain in 
patients with brucellosis with involvement of more than three 
major joints.22,23 
In the present study, it was found that there was a 
significant difference on the fourth day post-treatment between 
gabapentin and naproxen. the reason can be attributed to the 
fact that for initiating effective analgesic therapy by 
gabapentin, it is necessary that the serum level of the drug 
reach a satisfactory level so that it can exert its analgesic effect. 
The results of this study revealed that gabapentin 
effectively and more rapidly reduced the skeletal pain in 
brucellosis patients and caused more satisfaction among 
patients. Thus, it can be used as an appropriate analgesic for the 
control of bone and joint pain in brucellosis patients. However, 
since the onset of its effects requires a proper level of the drug, 
it is necessary to use it for at least several days. 
The limitations of this research included the lack of 
cooperation of patients in determining the severity of pain due 
to impatience. This problem was largely overcome through the 
patience of the executives and changing the timing. Also, in 
case the patients felt that despite the explanation and 
justification of the presenters, they did not have the proper 
cooperation to express their pain severity, the patient would be 
excluded from the study and replaced with another patient. 
Table 3. Frequency distribution of patients in two groups based on the mean of pain intensity at different times 
Pvalue 
Control group 
Mean (95% CI) VAS 
Intervention group 
Mean (95% CI) VAS 
Time 
0.128 8.1 (7.8-8.3) 8.2 (7.8-8.4) Before intervention 
0.062 7.8 (7.5-8.1) 7.4 (7.1-7.6) At the end of the fourth day 
0.021 6.4 (6.2-6.7) 4.9 (4.7-5.2) At the end of the seventh day 
0.001 5.7 (5.5-5.9) 3.8 (3.6-4.0) At the end of the tenth day 
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